AC 165198

Drug Profile

AC 165198

Alternative Names: AC-165198; Phybrid

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Amylin Pharmaceuticals; Biocon
  • Developer Amylin Pharmaceuticals
  • Class Hormones; Peptide hormones; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetes mellitus; Obesity

Most Recent Events

  • 14 Aug 2013 AC 165198 is still in phase I trials for Diabetes mellitus & Obesity
  • 07 Jan 2013 Biocon terminates its partnership with Amylin for AC 165198
  • 08 Aug 2012 Amylin Pharmaceuticals has been acquired by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top